



Carcinoembryonic Antigen (CEA) Test System Product Code: 1825-300

1.0 INTRODUCTION

Intended Use: The Quantitative Determination of Carcinoembryonic Antigen (CEA) Concentration in Human Serum by a Microplate Immunoenzymometric assay.

2.0 SUMMARY AND EXPLANATION OF THE TEST

Carcinoembryonic antigen (CEA) is a glycoprotein with a molecular weight of 180 kDA. CEA is the first of the so-called carcinoembryonic proteins that was discovered in 1965 by Gold and Freeman (1). CEA is the most widely used marker for gastrointestinal cancer.

Although CEA is primarily associated with colorectal cancers (CRC), other malignancies that can cause elevated levels of CEA include breast, lung, stomach, pancreas, ovary and other organs. Benign conditions that cause significantly higher than normal levels include inflammation of lung and gastrointestinal (GI) tract and benign liver cancer ^(2, 3). Heavy Smokers, as a group, have higher than normal baseline concentration of CEA. Serum values in healthy adults are normally \leq 5.0 ng/ml however, serum values exceeding 5 times the normal reference range are taken as indicative of malignancy. Also, values seen in malignant and nonmalignant conditions can overlap thus making CEA a not very dependable marker for malignancy. However, the real importance of CEA testing lies in patient prognosis, status assessment and monitoring. Monitoring CEA levels during chemotherapy and before surgery can be informative; the failure of CEA levels to fall during pre-operative radiotherapy usually indicates the presence of a tumor outside the field of radiation and a poor prognosis. Levels have been seen to drop to normal in 4-6 weeks after a successful resection of CRC.

In this method, CEA calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies, directed against distinct and different epitopes of CEA, are added then the reactants mixed. Reaction between the various CEA antibodies and native CEA forms a sandwich complex that binds with the streptavidin coated to the well.

After the completion of the required incubation period, the enzyme-CEA antibody bound conjugate is separated from the unbound enzyme-CEA conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce color.

The employment of several serum references of known carcinoembryonic antigen (CEA) levels permits the construction of a dose response curve of activity versus concentration. From

comparison to the dose response curve, an unknown specimen's activity can be correlated with CEA concentration.

3.0 PRINCIPLE

Immunoenzymometric assay (TYPE 3):

The essential reagents required for an immunoenzymometric assay include high affinity and specificity antibodies (enzyme and immobilized), with different and distinct epitope recognition, in excess, and native antigen. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinvlated monoclonal anti-CEA antibody.

Upon mixing monoclonal biotinylated antibody, the enzymelabeled antibody and a serum containing the native antigen, reaction results between the native antigen and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex. The interaction is illustrated by the following equation:

 $\begin{array}{c} \mathsf{Enz}_{\mathsf{Ab}} + \mathsf{Ag}_{\mathsf{CEA}} + {}^{\mathsf{Bin}} \mathsf{Ab}_{(m)} & \underbrace{}_{\mathsf{K_{2a}}} {}^{\mathsf{Enz}} \mathsf{Ab} \cdot \mathsf{Ag}_{\mathsf{CEA}} {}^{\mathsf{Bin}} \mathsf{Ab}_{(m)} \end{array}$ ^{Btn}Ab_(m) = Biotinylated Monoclonal Antibody (Excess Quantity)

- Ag_{CFA} = Native Antigen (Variable Quantity)
- EnzAb = Enzyme labeled Antibody (Excess Quantity)
- EnzAb -Ag_{CEA}-^{Btn}Ab_(m) = Antigen-Antibodies Sandwich Complex
- k_a = Rate Constant of Association
- k_{2} = Rate Constant of Dissociation

Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody. This interaction is illustrated below.

 ${}^{Enz}\!Ab \ \text{-Ag}_{CEA} \hbox{-}^{Btn}\!Ab_{(m)} + Streptavidin_{C.W.} \Rightarrow Immobilized \ complex$

Streptavidin_{C.W.} = Streptavidin immobilized on well

Immobilized complex = sandwich complex bound to the well

After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is directly proportional to the native antigen concentration. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

4.0 REAGENTS

B.

Materials Provided:

- Carcinoembryonic antigen (CEA) 1ml/vial Icons A-F Six (6) vials of references CEA Antigen at levels of O(A). 5(B), 10(C), 25(D), 50(E) and 250(F) ng/ml. Store at 2-8°C. A preservative has been added.
 - Note: The calibrators, human serum based, were calibrated using a reference preparation, which was assayed against the 1st International Reference Preparation (IRP# 73/601).
- CEA Enzyme Reagent 13ml/vial Icon 🖲 One (1) vial containing enzyme labeled antibody, biotinylated monoclonal mouse IgG in buffer, dye, and
- preservative. Store at 2-8°C. Streptavidin Coated Plate - 96 wells - Icon[#] C. One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.
- D. Wash Solution Concentrate – 20 ml - Icon 🌢 One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.
- E. Substrate A – 7ml/vial - Icon S⁴ One (1) bottle containing tetramethylbenzidine (TMB) in buffer. Store at 2-8°C.

Substrate B – 7ml/vial - Icon S^B F.

One (1) bottle containing hydrogen peroxide (H₂O₂) in buffer. Store at 2-8°C.

- Stop Solution 8ml/vial Icon G. One (1) bottle containing a strong acid (1N HCl). Store at 2-30°C.
- Product Instructions. I.

Note 1:Do not use reagents beyond the kit expiration date. Note 2:Opened reagents are stable for sixty (60) days when stored at 2-8°C. Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component

stability are identified on the label. Note 3: Above reagents are for a single 96-well microplate.

4.1 Required But Not Provided:

- 1. Pipette(s) capable of delivering 25µl,& 50µl volumes with a precision of better than 1.5%.
- 2. Dispenser(s) for repetitive deliveries of 0.100ml and 0.350ml volumes with a precision of better than 1.5%.
- 3. Microplate washers or a squeeze bottle (optional). 4. Microplate Reader with 450nm and 620nm wavelength absorbance capability.
- 5. Absorbent Paper for blotting the microplate wells.
- 6. Plastic wrap or microplate cover for incubation steps.
- 7. Vacuum aspirator (optional) for wash steps.
- 8. Timer. 9. Quality control materials

5.0 PRECAUTIONS

For In Vitro Diagnostic Use Not for Internal or External Use in Humans or Animals

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA licensed reagents. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories." 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

Safe Disposal of kit components must be according to local regulatory and statutory requirement.

6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood, serum in type and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants. Allow the blood to clot. Centrifuge the specimen to separate the serum from the cells.

In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml of the specimen is required.

7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and elevated range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. Significant deviation from established performance can

indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

8.0 REAGENT PREPARATION:

1. Wash Buffer

Dilute contents of wash solution to 1000ml with distilled or deionized water in a suitable storage container. Store at 2-30°C for up to 60 days

2. Working Substrate Solution

Pour the contents of the amber vial labeled Solution 'A' into the clear vial labeled Solution 'B'. Place the yellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2 - 8°C.

Note 1:Do not use the working substrate if it looks blue. Note2:Do not use reagents that are contaminated or have

bacteria growth.

9.0 TEST PROCEDURE

Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (20 - 27°C). **Test Procedure should be performed by a skilled individual or trained professional**

- 1. Format the microplates' wells for each serum reference, control and patient specimen to be assayed in duplicate. Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.
- 2. Pipette 0.025 ml (25µl) of the appropriate serum reference. control or specimen into the assigned well
- 3. Add 0.100 ml (100µl) of the CEA Enzyme Reagent to each well. It is very important to dispense all reagents close to the bottom of the coated well.
- 4. Swirl the microplate gently for 20-30 seconds to mix and cover. 5. Incubate 60 minutes at room temperature.
- 6. Discard the contents of the microplate by decantation or
- aspiration. If decanting, tap and blot the plate dry with absorbent paper.
- 7. Add 350µl of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.
- 8. Add 0.100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). Always add reagents in the same order to minimize reaction time differences between wells.

DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION

- 9. Incubate at room temperature for fifteen (15) minutes.
- 10. Add 0.050ml (50µl) of stop solution to each well and mix gently for 15-20 seconds. Always add reagents in the same order to minimize reaction time differences between wells.
- 11. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. The results should be read within thirty (30) minutes of adding the stop solution.

10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of Carcinoembryonic antigen in unknown specimens.


- 1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
- 2. Plot the absorbance for each duplicate serum reference versus the corresponding CEA concentration in ng/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
- 3. Draw the best-fit curve through the plotted points.
- 4. To determine the concentration of CEA for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the

average absorbance (0.391 Abs) intersects the dose response curve at (22.5 ng/ml) CEA concentration (See Figure 1).

Note: Computer data reduction software designed for ELISA assays may also be used for the data reduction. If such software is utilized, the validation of the software should be ascertained.

EXAMPLE 1					
Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (ng/ml)	
Cal A	A1	0.017	0.018	0	
	B1	0.019	0.010		
Cal B	C1	0.160	0.159	5	
	D1	0.159	0.159		
Cal C	E1	0.231	0.227	10	
Carc	F1	0.224	0.227		
Cal D	G1	0.431	0.424	25	
Carb	H1	0.418	0.424		
Cal E	A2	0.776	0.770	50	
	B2	0.763	0.770		
Cal F	C2	2.851	2.866	250	
	D2	2.880	2.000	230	
Patient	E2	0.398	0.391	22.5	
Patient	F2	0.384	0.391	22.5	

Figure 1



*The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay.

11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

1. The absorbance (OD) of calibrator F should be \geq 1.3. 2. Four out of six quality control pools should be within the

established ranges.

12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

12.1 Assay Performance

- 1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
- 2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
- Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
 If more than one (1) plate is used, it is recommended to
- If more than one (1) plate is used, it is recommended to repeat the dose response curve.

- The addition of substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
- 6. Plate readers measure vertically. Do not touch the bottom of the wells.
- Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
- Use components from the same lot. No intermixing of reagents from different batches.
- Patient specimens with CEA concentrations above 250 ng/ml may be diluted (for example 1/10 or higher) with normal serum (CEA < 5 ng/ml) and re-assayed. The sample's concentration is obtained by multiplying the result by the dilution factor (10).
- Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind's IFU may yield inaccurate results.
- All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
- 12. It is important to calibrate all the equipment e.g. pipettes, readers, washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
- Risk Analysis- as required by CE Mark IVD Directive 98/79/EC

 for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

12.2 Interpretation

smokers

- 1. Measurements and interpretation of results must be performed by a skilled individual or trained professional.
- Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
- 3. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
- If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, <u>Monobind shall have no liability</u>.
- If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
- 6. CEA has a low clinical sensitivity and specificity as a tumor marker. Clinically an elevated CEA value alone is not of diagnostic value as a test for cancer and should only be used in conjunction with other clinical manifestations (observations) and diagnostic parameters. There are patients with colorectal cancer that do not exhibit elevated CEA values and elevated CEA values do not always change with progression or regression of disease. Smokers demonstrate a higher range of baseline values than non-

13.0 EXPECTED RANGES OF VALUES

Nearly 99% of non-smokers have CEA concentrations less than 5ng/ml. Similarly 99% of smokers have concentrations less than 10ng/ml $^4.$

	I ABLE 1			
Expected	Values for	the CEA	Elisa	Test System

Non-smokers	<5ng/ml	Smokers	<10ng/ml

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal"-persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the Manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

14.0 PERFORMANCE CHARACTERISTICS

14.1 Precision

The within assay precision of the CEA AccuBind[®] Microplate EIA Test System were determined by analyses on six different levels of pool control and patient sera. The mean values, standard deviation and coefficient of variation for each of these control sera are presented in Table 2.

TABLE 2 Precision data for the CEA Test System

Sample	Mean Value (ng/ml)	Within-Run Precision SD CV%		Total Pi (n=	recision 80) CV%
Control 1	5.6	0.29	5.19	0.76	13.62
Control 2	23.9	1.03	4.30	2.02	8.45
Control 3	50.2	1.71	3.41	3.80	7.57
Patient 1	13.8	0.74	5.37	1.62	11.75
Patient 2	63.5	1.90	2.99	5.80	9.13
Patient 3	121.6	6.65	5.47	16.19	13.32
*As measured in forty experiments in duplicate over a 20 day					

*As measured in forty experiments in duplicate over a 20 day period.

14.2 Sensitivity

The CEA AccuBind® ELISA test system has a LoB = 0.499 ng/ml and a LoD = LoQ = 0.816 ng/ml.

14.3 Accuracy 14.3.1 Linearity

The linearity of the CEA Accubind[®] ELISA test system was tested by diluting human serum samples containing high levels of CEA (62 to 269 ng/ml) with low CEA (<1 ng/ml) human serum samples. The results confirm that there is linearity across various sample preparations throughout the range of the test to 269 ng/ml.

14.3.2 Recovery

The recovery of the CEA AccuBind[®] Microplate ELISA Test System was calculated for five patient samples spiked with varying levels of CEA up to 225 ng/ml. Recoveries were determined to be within 15% of the expected values for all samples.

14.3.3 Method Comparison

The CEA AccuBind[®] ELISA method was compared with a reference Elisa method. Biological specimens from normal and elevated concentrations were assayed. The total number of such specimens was 202. The least square regression equation and the correlation coefficient were computed for the CEA AccuBind[®] ELISA method in comparison with the reference method. The data obtained is displayed in Table 4.

TABLE 4

Method	Mean	Least Square Regression Analysis	Correlation Coefficient
This Method(X)	5.67	y = -0.1164+1.0324x	0.935
Reference (Y)	5.75		

14.4 Specificity:

Highly specific antibodies to CEA molecules have been used in the CEA AccuBind[®] ELISA test system. No interference was detected with the performance of CEA AccuBind[®] ELISA upon addition of massive amounts of the following substances to a human serum pool.

Substance	Concentration
Acetylsalicylic Acid	100 µg/ml
Ascorbic Acid	100 µg/ml
Caffeine	100 µg/ml
AFP	10 µg/ml
PSA	1.0 µg/ml
CA-125	10,000 U/ml
hCG	1000 IU/ml
hLH	10 IU/ml
hTSH	100 mIU/ml
hPRL	100 µg/ml

14.5 High Dose Hook Effect:

The high dose hook effect of the CEA AccuBind® ELISA was assessed using several samples containing massive concentrations of CEA (> 60,000 ng/ml).

The test showed no hook effect up to concentrations of 60,000 ng/ml.

15.0 REFERENCES

- 1 Gold P, Freedman SO, *J Exp Med* , **121**, 439 (1965).
- 2. Zamcheck N, Adv Intern Med, 19, 413 (1974).
- 3. Rayncao G, Chu TM, JAMA, 220, 381 (1972).
- Wild D, The Immunoassay Handbook, Stockton Press, 444 (1994).
- Sorokin JJ, Sugarbaker PH, Zamcheck N, Pisick M, Kupchik HZ, Moore FD, "Serial carcinoemryonic antigen assays. Use in detection of cancer recurrence", *JAMA*, 228,49-53 (1974).
- Mackay AM, Patel S, Carter S, Stecens U, Lawrence DJR, Cooper EH, et al. "Role of serial plasma assays indetection of recurrent and metastatic colorectal carcinomas". Br. Med. Jr. 1974: 4:382-385.
- Sikorska H, Schuster J, Gold P, "Clinical applications of carcinoembryonic antigen", *Cancer Detection Preview*, 12, 321-355 (1988).
- Minton JP, Martin EW Jr,"The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second-look surgery", *Cancer*, 42, 1422-27 (1978).
- Staab HJ, Anderer FA, Stumpf E, Fischer R. "Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal carcinoma". Am. J.Surgery;136:322-327 (1978).
- Thomas P, Toth CA, Saini KS, Jesup JM, Steele G Jr, "The structure, metabolism and function of carcinoembryonic antigen gene family", *Biochem Biophys Acta*, **1032**,177-189 (1990).
- Yamashita K, Totami K, Kuroki M, Ueda I, Kobata A, "Structural studies of the carbohydrate moieties of carcinoembryonic antigens", *Cancer Research*, 47, 3451-3459 (1987).
- Hammerstrom S, Shively JE, Paxton RJ, Beatty BG, Larson A, Ghosh R, et al, "Antigenic sites in carcinoembryonic antigen", *Cancer Research*, 49,4852-58 (1989).
- National Institute of Health, "Carcinoembryonic Antigen: Its role as a marker in the management of cancer; A national Institute of Health Consensus Development Conference", Ann Inter Med, 94,407-409 (1981).

Revision: 5 Date: 2021-Oct-04 DCO: 1515 MP1825 Product Code: *1825-300*

	Size		96(A)	192(B)
		A)	1ml set	1ml set
	Reagent (fill)	B)	1 (13ml)	2 (13ml)
		C)	1 plate	2 plates
		D)	1 (20ml)	1 (20ml)
		E)	1 (7ml)	2 (7ml)
		F)	1 (7ml)	2 (7ml)
		G)	1 (8ml)	2 (8ml)

For Orders and Inquiries, please contact



Tel: +1 949.951.2665 Email: info@monobind.com Fax: +1 949.951.3539 Web: <u>www.monobind.com</u>

Please visit our website to learn more about our other interesting products and services.



